FDA Approves Supplemental Application for REXTOVY by Amphastar Pharmaceuticals
The FDA has approved a supplemental application for REXTOVY, containing naloxone hydrochloride.
Company
Pharmaceutical intelligence for Amphastar Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.